Category: C-DOCTOR News

C-DOCTOR receives another CIRM Conference Grant in support of the 2024 C-DOCTOR Retreat

In April 2024, C-DOCTOR receives the CIRM Conference Grant in support of the annual C-DOCTOR retreat. The conference will be held in Berkeley, CA, in June 3-4, 2024. The objective of the CIRM Conference Grant is to support valuable mission-specific scientific conferences where people assemble to exchange scientific information and explore specific scientific subject relevant to CIRM’s mission. Under this program, the C-DOCTOR retreat aligns with CIRM’s short and long-term goals and addresses critical topics related to stem cell-based therapy and discovery/stem cell biology. 

2024 IADR/AADOCR/CADR General Session & Exhibition

Please join us as the International Association for Dental, Oral, and Craniofacial Research (IADR) will host its 102nd General Session & Exhibition with the 53rd Annual Meeting of the American Association for Dental, Oral, and Craniofacial Research (AADOCR) and the 48th Annual Meeting of the Canadian Association for Dental Research (CADR). This event will be hosted in New Orleans, Louisiana, USA, March 13-16, 2024. This event will feature success stories in the product development journey from projects/small businesses that used various NIDCR funding mechanisms along with many prestigious guest speakers. Click the following links to learn more: https://www.nidcr.nih.gov/news-events/events/2024/nidcr-75-accelerating-product-innovation-development-research-commercialization https://www.aadocr.org/2024iags  

Save the Date for the 2024 C-DOCTOR Spring Retreat

Please join us at the 2024 C-DOCTOR Spring Retreat on June 3-4, 2024 at the Marriott Residence Inn in Berkeley, CA.

First Successful C-DOCTOR IND Filing!

C-DOCTOR celebrates Dr. Derrick Wan’s successful IND filing for their interdisciplinary translational project “Transdermal Deferoxamine to Enhance Fat Graft Retention for Reconstruction of Irradiated Soft Tissue Defects” (Deferoxamine Patch for Radiation-Injured Skin)!” Their team filed the IND application on November 30, 2023, and received their “study may proceed” letter on January 3, 2024, allowing them to begin their clinical trial. The Deferoxamine Patch for Radiation-Injured Skin ITP is the very first C-DOCTOR ITP to successfully file an IND application since C-DOCTOR has been established. This is a landmark achievement for Dr. Wan, C-DOCTOR, and DOCTRC (Dental, Oral and Craniofacial Tissue Regeneration Consortium). C-DOCTOR has worked diligently and efficiently with the Wan ITP team to ensure that they have all the necessary resources to file a successful IND and graduate from the C-DOCTOR program. The Deferoxamine Patch for Radiation-Injured Skin ITP team has developed a transdermal patch delivery system for an FDA-approved medication, deferoxamine, to treat chronic, fibrotic radiation-injured soft tissue. Preclinical studies showed that injection of this medication into irradiated tissue results in improved blood flow and tissue quality. Given the frequency and severity of debilitating radiotherapy side effects and limited available treatment options, their novel approach meets a large clinical need with potential for rapid clinical adoption. The next step for Dr. Wan is to secure funding for a first-in-human clinical trial as C-DOCTOR does not support clinical trials. We congratulate Dr. Wan and his team for this exciting feat and what it means for C-DOCTOR. We hope this inspires all the ITP teams working towards their approval for clinical trials.

DOCTRC successfully hosts their 4th Annual Joint Retreat in Los Angeles, CA December 4–6, 2023

The 2023 4th Annual Joint DOCTRC was hosted at the USC Health Sciences Conference Center. The Dental, Oral, and Craniofacial Tissue Regeneration Consortium (DOCTRC) is comprised of two NIH-funded resource centers, the Center for Dental, Oral & Craniofacial Tissue & Organ Regeneration (C-DOCTOR) and the Michigan-Pittsburgh-Wyss Regenerative Medicine (MPWRM) Resource Center. These resource centers receive funding from the National Institute of Dental and Craniofacial Research (NIDCR) with the mission to shepherd new therapies through pre-clinical studies and into human clinical trials, commercialization, and broad clinical adoption.  The event highlighted the progress of the projects in each Resource Center’s Interdisciplinary Translational Project portfolio and feature keynote speeches from Srinivas Nandkumar, PhD (US Food and Drug Administration’s Center for Radiological and Device Health, Director of Dental and ENT Devices) and Dr. Rena D’Souza, DDS, MS, PhD (NIDCR, Director). There was also a special presentation from the retreat’s co-funder, the California Institute for Regenerative Medicine (CIRM) by Lisa Kadyk, PhD.  The retreat was an excellent opportunity for attendees to connect with other project teams, the DOCTRC leadership, NIDCR program staff, DOCTRC operations staff, and external advisors and consultants to network and collaborate.

Wan ITP Team Files IND!

Congratulations to the “Transdermal Deferoxamine For Treatment Of Irradiated Soft Tissue” ITP team led by Derrick Wan on their IND submission.

Hydronovo ITP receives $2.3 million CIRM Translational Research Grant

On October 27, 2023 – C-DOCTOR Interdiscplinary Translational Project Team, Hydronovo, received a $2.3 million California Institute for Regenerative Medicine (CIRM) Translational Stage research grant to fund development of their small molecule therapy and related translational activities. This funding, leveraged in addition to the funding and support for proof-of-concept studies provided by C-DOCTOR and the National Institutes of Health/National Institute of Dental and Craniofacial Research, will enable their goal of completing pivotal preclinical studies ahead of IND filing with the FDA. The Hydronovo team (consisting of principal investigators, Sarah Knox, PhD, Chelsea Bahney, PhD, and Eben Alsberg, PhD) takes a monumental step towards clinical trials with their outstanding accomplishment in receiving this grant. The CIRM Translational Stage grant mechanism is a highly competitive opportunity for promising regenerative medicine projects that accelerate completion of translational stage activities necessary for advancement to clinical study. Hydronovo’s product will advance CIRM’s mission to accelerate world class science to deliver transformative regenerative medicine treatments. With funding from this CIRM grant, Hydronovo’s product is one step closer to reaching clinical adoption. Xerostomia, or dry mouth, affects over 8 million U.S citizens due to salivary dysfunction which severely decreases oral health and quality of life. The goal of Hydronovo’s proposed product is to overcome radiation-induced xerostomia/dry mouth through neurogenic stimulation of salivary gland stem cells. Hydronovo will use this grant to focus on safety and dosing studies in a large animal model; R&D grade Ceviginate production; quality controls/analytical protocol development and validation, packaging stability testing/aging, and first-in-human (FIH) clinical trial design development. With no regenerative treatments available, they plan to fulfill this unmet need by developing a long-term therapeutic treatment to restore salivary flow through activating salivary gland regeneration. Hydronovo expressed, “This will be the first regenerative treatment for this medical condition and gives cancer survivors and their families the chance to restore their quality of life.” Click here to read more: https://www.cirm.ca.gov/about-cirm/newsroom/press-releases/cirm-invests-more-than-42-million-in-translational-stage-research/ Click here to read more about the Hydronovo ITP: https://c-doctor.org/wp-content/uploads/2023/06/Hydronovo-Salivary-Gland-Regeneration-Knox.pdf

C-DOCTOR receives the CIRM Conference Grant in Support of the 2023 DOCTRC Retreat

In October 2023, C-DOCTOR receives the CIRM Conference Grant in support of the 4th Annual Joint 2023 DOCTRC Retreat with C-DOCTOR and the MPWRM Resource Center. The conference will be held in Los Angeles, December 4-6. The objective of the CIRM Conference Grant is to support valuable mission-specific scientific conferences where people assemble to exchange scientific information and explore specific scientific subject relevant to CIRM’s mission. Under this program, the joint DOCTRC retreat aligns with CIRM’s short and long-term goals and addresses critical topics related to stem cell-based therapy and discovery/stem cell biology. 

C-DOCTOR PI, Dr. Yang Chai, wins 2023 Harvard School of Dental Medicine’s Paul Goldhaber Award

From the Herman Ostrow School of Dentistry of USC: ASSOCIATE DEAN OF RESEARCH Yang Chai PhD ’91, DDS ’96 has been awarded the 2023 Paul Goldhaber Award by the Harvard School of Dental Medicine. The highest honor given by the school, the award goes to a recipient who is held in the highest international esteem in his or her field relating to oral and systemic health. The award letter notes Chai’s “outstanding national and international contributions to teaching and research in oral health science.” Click here to read more: https://dentistry.usc.edu/university-professor-yang-chai-wins-2023-harvard-school-of-dental-medicines-paul-goldhaber-award/ https://www.thecrimson.com/article/2023/10/18/yang-chai-goldhaber-award/

DOCTRC presents at the 2023 IADR Annual Meeting

C-DOCTOR and DOCTRC deliver an interactive talk titled “DOCTRC: A Consortium Accelerating Tissue Engineering/Regenerative Medicine Therapies” to share about DOCTRC’s efforts to serve as the nation’s consortium for accelerating regenerative therapies for dental, oral, and craniofacial tissues towards clinical adoption and product commercialization.